Validity, test-retest reliability, and responsiveness of the Indonesian version of FACIT-COST measure for subjective financial toxicity
This is the first study to validate the FACIT-COST in patients with breast cancer and to present the measurement properties of the Indonesian version of FACIT-COST. The Indonesian FACIT-COST demonstrates acceptable psychometric performance and shows potential as a valid measure of subjective financial toxicity. The instrument may serve as a valuable tool for informing health policies that focus on providing resource support to improve cancer care in Indonesia.
Authors
- Fanni Rencz (ORCID: https://orcid.org/0000-0001-9674-620X)
- Stevanus Pangestu (ORCID: https://orcid.org/0000-0003-2546-9449)
- Clara Mukuria (ORCID: https://orcid.org/0000-0003-4318-1481)
- Hari Setyowibowo (ORCID: https://orcid.org/0000-0001-5091-3180)
- Fredrick Dermawan Purba (ORCID: https://orcid.org/0000-0002-7336-3043)
Institutions
- Atma Jaya Catholic University of Indonesia (ID)
- Corvinus University of Budapest (HU)
- University of Sheffield (GB)
- Padjadjaran University (ID)
Publication Details
- Journal
- Health and Quality of Life Outcomes
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1186/s12955-024-02303-5
- Citations
- 2
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- EuroQol Research Foundation